Outcomes of different treatment opproaches for gastro-oesophageal reflux disease

  • J. Labenz
Conference paper
Part of the Falk Symposium book series (FASS, volume 160)

Abstract

Gastro-oesophageal reflux disease (GORD) is a common condition affecting around 20% of the adult population of industrialized countries1. In a recent population-based study from Sweden as much as 45% of the adult population suffered from reflux symptoms, and 15% had erosive oesophagitis on endoscopy2. A systematic review of the literature clearly demonstrated a significant increase of reflux symptoms and GORD in US and European populations. Based on these epidemiological data, optimizing the initial and long-term management of this disease has beyond, doubt high priority.

Keywords

CHES 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Locke GR, Talley NJ, Fett SL et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted county., Gastroenterology. 1997;112:448–56.Google Scholar
  2. 2.
    Ronkainen J, Aro P, Storskrubb T et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol. 2005;40:275–85.PubMedCrossRefGoogle Scholar
  3. 3.
    El-Serag H. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17–26.PubMedCrossRefGoogle Scholar
  4. 4.
    Vakil NV, van Zanten S, Kahrilas P et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20.PubMedCrossRefGoogle Scholar
  5. 5.
    Morgner-Miehlke A, Koop H, Blum AL et al. Abklärung und Therapie von Refluxbeschwerden. Z Gastroenterol. 2006;44:399–410.PubMedCrossRefGoogle Scholar
  6. 6.
    Hansen NA, Bergheim R, Fagertun H et al. A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease. Int J Clin Pract. 2005;59:665–71.CrossRefGoogle Scholar
  7. 7.
    Dean BB, Gano Jr AD, Knight K et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Armstrong D, Talley NJ, Lauritsen K et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004;20:413–21.PubMedCrossRefGoogle Scholar
  9. 9.
    Broekaert D, Fischler B, Sifrim D et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo controlled study. Aliment Pharmacol Ther. 2006;23:365–70.PubMedCrossRefGoogle Scholar
  10. 10.
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–810.PubMedCrossRefGoogle Scholar
  11. 11.
    Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Labenz J, Armstrong D, Lauritsen K et al. A randomised comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther. 2005;21:739–46.PubMedCrossRefGoogle Scholar
  13. 13.
    Richter JE, Kahrilas PJ, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol, 2001;96:656–65.PubMedCrossRefGoogle Scholar
  14. 14.
    Malfertheiner P, Lind T, Willich S et al. Prognostic influence of Barrett’s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut. 2005;54:746–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Labenz J, Malfertheiner P. Treatment of uncomplicated reflux disease. World J Gastroenterol. 2005;11:4291–9.PubMedGoogle Scholar
  16. 16.
    Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors use in general practice in England: cohort studies. Br J Pharmacol. 2000;50:366–72.CrossRefGoogle Scholar
  17. 17.
    Labenz J, Petersen KU, Rösch W, Koelz R. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and patoprazole. Aliment Pharmacol Ther. 2003;17:1015–19.PubMedCrossRefGoogle Scholar
  18. 18.
    Hunfeld HGM, Geus WP, Kuipers EJ. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther. 2007;25:39–46.PubMedCrossRefGoogle Scholar
  19. 19.
    Carlsson R, Dent J, Watts R et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10:119–24.PubMedCrossRefGoogle Scholar
  20. 20.
    Dent J. Management of reflux disease. Gut. 2002;50(Suppl. IV):iv67–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Bardhan KD, Müller-Lissner S Bigard MS et al. Symptomatic gastro-oesophageal reflux disease: double-blinded controlled study of intermittent treatment with omeprazole or ranitidine. Br Med J 1999;318:502–7.Google Scholar
  22. 22.
    Bytzer P, Blum AL. Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20:389–98.PubMedCrossRefGoogle Scholar
  23. 23.
    Fennerty MB. Review article: Alternative approaches to the long-term management of GERD. Aliment Pharmacol Ther. 2005;22(Suppl. 3):39–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Labenz J, Morgner-Miehlke A. An update on the available treatments for non-erosive reflux disease. Expert Opin Pharmacother. 2006;7:47–56.PubMedCrossRefGoogle Scholar
  25. 25.
    Johnson DA, Benjamin SB, Vakil NB et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96:27–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001;15:927–35.PubMedCrossRefGoogle Scholar
  27. 27.
    Sjöstedt S, Befrits R, Sylvan A et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther. 2005;22:183–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr. 2007;150:262–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Klinkenberg-Knol E, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Laheij RJ, Sturkenboom MC, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. J Am Med Assoc. 2004;292:1955–60.CrossRefGoogle Scholar
  31. 31.
    Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. J Am Med Assoc. 2006;296:2947–53.CrossRefGoogle Scholar
  32. 32.
    Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:1–10.CrossRefGoogle Scholar
  33. 33.
    Vakil N. Review article: The role of surgery in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007;25:1365–72.PubMedCrossRefGoogle Scholar
  34. 34.
    Laine L, Ahnen D, McClain C et al. Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14:651–68.PubMedCrossRefGoogle Scholar
  35. 35.
    Shaheen NJ. The rise and fall (and rise?) of endoscopic anti-reflux procedures. Gastroenterology. 2006;131:952–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Corley DA, Katz P, Wo JM et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized sham-controlled trial. Gastroenterology. 2003;125:668–76.PubMedCrossRefGoogle Scholar
  37. 37.
    Deviere J, Costamagna G, Neuhaus H et al. Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multicenter trial. Gastroenterology. 2005;128:532–40.PubMedCrossRefGoogle Scholar
  38. 38.
    Schwartz MP, Wellink H, Gooszen HG et al. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. Gut. 2007;56:20–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Schiefke I, Zabel-Langhenning A, Neumann S et al. Long-term failure of endoscopic gastroplication (EndoCinch). Gut. 2005;54:752–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Schiefke I, Neumann S, Zabel-Langhenning A et al. Use of an endoscopic suturing device (the ‘ESD’) to treat patients with gastroesophageal reflux disease, after unsuccessful EndoCinch endoluminal gastroplication: another failure. Endoscopy. 2005;37:700–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Rothstein R, Filipi C, Caca K et al. Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: a randomized, sham-controlled trial. Gastroenterology. 2006;131:704–12.PubMedCrossRefGoogle Scholar
  42. 42.
    Pleskow D, Rothstein R, Lo S et al. Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial. Gastrointest Endosc. 2005;61:643–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Kahrilas PJ. Laparoscopic antireflux surgery: silver bullet or the emperor’s new clothes? Am J Gastroenterol. 1999;94:1721–3.PubMedCrossRefGoogle Scholar
  44. 44.
    Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic antireflux fundoplication in a U.S. community. Am J Med. 2003;114:1–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Thibault R, Coron E, Sébille V et al. Antireflux surgery for non-erosive and erosive reflux disease in community praxis. Aliment Pharmacol Ther. 2006;24:621–32.PubMedCrossRefGoogle Scholar
  46. 46.
    Lundell L, Miettinen P, Myrvold HE et al. Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis. Br J Surg. 2007;94:198–203.PubMedCrossRefGoogle Scholar
  47. 47.
    Bojke L, Hornby E, Sculpher M. A comparison of the cost effectiveness of pharmacotherapy or surgery (laparoscopic fundoplication) in the treatment of GORD. Pharmacoeconomics. 2007;25:829–41.PubMedCrossRefGoogle Scholar
  48. 48.
    Myrvold HE, Lundell L, Miettinen P et al. The cost of long term therapy for gastroesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gut. 2001;49:488–94.PubMedCrossRefGoogle Scholar
  49. 49.
    Tran T, Spechler SJ, Richardson P et al. Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans affairs cohort study. Am J Gastroenterol. 2005;100:1002–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer and Falk Foundation e.V. 2008

Authors and Affiliations

  • J. Labenz
    • 1
  1. 1.Department of Internal Medicine and Gastroenterology Jung-Stilling HospitalAcademic Teaching Hospital of the University of BonnSiegenGermany

Personalised recommendations